Bulletin
Investor Alert

New York Markets Close in:

Revolution Medicines Inc.

NAS: RVMD

GO
/marketstate/country/us

Market open

 --Real time quotes

Oct 4, 2022, 12:25 p.m.

/zigman2/quotes/216320743/composite

$

19.53

Change

+0.0000 +0.0000%

Volume

Volume 122,128

Real time quotes

/zigman2/quotes/216320743/composite

Previous close

$ 19.53

$ 19.53

Change

+0.0000 +0.0000%

Day low

Day high

$19.53

$20.49

Open

52 week low

52 week high

$14.08

$34.16

Open

Barbara L. Weber

Barbara L. Weber holds the position of President, Chief Executive Officer & Director at Tango Therapeutics, Inc., President, Chief Executive Officer & Director at Tango Therapeutics Sub, Inc. (a subsidiary of Tango Therapeutics, Inc.) and Venture Partner at Third Rock Ventures LLC. Dr. Weber is also on the board of Revolution Medicines, Inc., Fog Pharmaceuticals, Inc. and OPY Acquisition Corp. I and Member of American Society for Clinical Investigation and Member of American Association of Physician Specialists, Inc.

Barbara L. Weber previously occupied the position of Senior VP-Oncology Translational Medicine at Novartis AG, Chief Medical Officer of BioNTech US, Inc., VP-Oncology Discovery & Translational Medicine at GlaxoSmithKline LLC, Professor & Associate at the University of Pennsylvania and Assistant Professor at the University of Michigan.

Barbara L. Weber received an undergraduate degree and a doctorate from UW Medicine.

Transactions

Date Shares Transaction Value
06/16/2022 5,200   Award at $0 per share. 0
06/22/2021 3,617   Award at $0 per share. 0
02/04/2021 900   Disposition at $51.86 per share. 46,674
02/04/2021 4,100   Disposition at $50.02 per share. 205,082
02/04/2021 5,000   Derivative/Non-derivative trans. at $4.73 per share. 23,650
02/02/2021 5,336   Disposition at $45 per share. 240,120
02/02/2021 5,336   Derivative/Non-derivative trans. at $1.12 per share. 5,976
10/05/2020 7,196   Disposition at $36.17 per share. 260,280
10/05/2020 7,196   Derivative/Non-derivative trans. at $1.12 per share. 8,059
10/02/2020 804   Disposition at $36.02 per share. 28,961
10/02/2020 804   Derivative/Non-derivative trans. at $1.12 per share. 900
10/01/2020 2,000   Disposition at $34.76 per share. 69,520
10/01/2020 2,000   Derivative/Non-derivative trans. at $1.12 per share. 2,240
08/13/2020 333   Disposition at $28 per share. 9,324
08/13/2020 333   Derivative/Non-derivative trans. at $1.12 per share. 372
08/12/2020 1,667   Disposition at $28 per share. 46,676
08/12/2020 1,667   Derivative/Non-derivative trans. at $1.12 per share. 1,867
06/17/2020 1,808   Award at $0 per share. 0

Officers and Executives

Dr. Mark A. Goldsmith
Chairman, President & Chief Executive Officer
Dr. Margaret A. Horn
Chief Operating Officer & General Counsel
Mr. Jack Anders
Chief Financial Officer
Dr. Stephen M. Kelsey
President-Research & Development
Dr. Walter Reiher
Chief Information Officer
Dr. Xiao Lin Wang
Executive Vice President-Clinical Development
Dr. Sushil Patel
Director
Ms. Luan M. Wilfong
Senior Vice President-Human Resources
Mr. Jeff Cislini
Secretary, Senior Vice President & General Counsel
Dr. Eric Schmidt
Independent Director
Dr. Flavia Borellini
Independent Director
Dr. Lorence H. Kim
Independent Director
Ms. Elizabeth McKee Anderson
Independent Director
Mr. Alexis A. Borisy
Lead Independent Director
Dr. Thilo Schroeder
Independent Director
Dr. Barbara L. Weber
Independent Director
Link to MarketWatch's Slice.